Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 426

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 426
---

parties, our product revenues may suffer.

We
will need to further increase the size and complexity of our organization in the future, and we may experience difficulties in managing
our growth and executing our growth strategy.

Our
management and personnel, systems, and facilities currently in place may not be adequate to support our business plan and future growth.
As a result, we may need to further expand certain areas of our organization.

Our
need to effectively manage our operations, growth and various projects requires that we:

    ●
    continue
    to improve our operational, financial, management and regulatory compliance controls and reporting systems and procedures;

    ●
    attract
    and retain enough talented employees;

    ●
    manage
    our clinical trials effectively;

    ●
    manage
    our external manufacturing operations with contract research organizations effectively and in a cost-effective manner;

    ●
    manage
    our development efforts effectively while carrying out our contractual obligations to contractors and other third parties; and

27

In
addition, we may utilize the services of part-time outside consultants and contractors to perform several tasks for us, including tasks
related to compliance programs, clinical trial management, regulatory affairs, formulation development and other drug development functions.
Our growth strategy may entail expanding our use of consultants and contractors to implement these and other tasks going forward. If
we are not able to effectively expand our organization by hiring new employees and expanding our use of consultants and contractors,
we may be unable to successfully implement the tasks necessary to effectively execute on our planned research, development, manufacturing,
and commercialization activities and, accordingly, may not achieve our research, development and commercialization goals.

We
expect to face intense competition, often from companies with greater resources and experience than we have.

The
development and commercialization of drugs and medicines is highly competitive. We compete with a variety of multinational pharmaceutical
companies and specialized biotechnology companies, as well as products and processes being developed by universities and other research
institutions. Many of our competitors have developed, are developing, or will develop drugs and processes which may be competitive with
our drug candidates. Competitive products include those that have already been approved by medicines regulators and accepted by the medical
community and any new products that may enter the market. For some of our drug development programs / areas of interest, other treatment
options or products are currently available, under development, and may become commercially available in the future. If any of our product
candidates are approved for the diseases and conditions we are currently pursuing